![JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma -5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) | SpringerLink JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma -5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12185-019-02681-3/MediaObjects/12185_2019_2681_Figa_HTML.png)
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma -5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) | SpringerLink
![PDF] Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. | Semantic Scholar PDF] Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/74871d9e08424adc99c6feb73b6e1105f7d1457d/5-Figure1-1.png)
PDF] Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. | Semantic Scholar
![Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options - ScienceDirect Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419369364-gr1.jpg)
Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options - ScienceDirect
![Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial - The Lancet Haematology Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/5f17591f-9f36-4294-95d2-a36ed404adb0/gr1_lrg.gif)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial - The Lancet Haematology
![Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt.14.93/asset/images/medium/figure1.gif)
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
![Overall survival of patients with diffuse large B-cell lymphoma after... | Download Scientific Diagram Overall survival of patients with diffuse large B-cell lymphoma after... | Download Scientific Diagram](https://www.researchgate.net/publication/330523075/figure/fig5/AS:717559355682821@1548090890581/Overall-survival-of-patients-with-diffuse-large-B-cell-lymphoma-after-rituximab.png)
Overall survival of patients with diffuse large B-cell lymphoma after... | Download Scientific Diagram
![Figure 2 from Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma | Semantic Scholar Figure 2 from Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d23de430239326affb9e0ad4d2a1d22e050493f0/5-Figure2-1.png)
Figure 2 from Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma | Semantic Scholar
Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? | Haematologica
![Course of therapy, responses and outcomes. DLBCL, diffuse large B-cell... | Download Scientific Diagram Course of therapy, responses and outcomes. DLBCL, diffuse large B-cell... | Download Scientific Diagram](https://www.researchgate.net/profile/Paul-Maciocia/publication/287483095/figure/fig2/AS:329978152538112@1455684330191/Course-of-therapy-responses-and-outcomes-DLBCL-diffuse-large-B-cell-lymphoma-CR.png)
Course of therapy, responses and outcomes. DLBCL, diffuse large B-cell... | Download Scientific Diagram
![New agents and regimens for diffuse large B cell lymphoma | Journal of Hematology & Oncology | Full Text New agents and regimens for diffuse large B cell lymphoma | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-020-01011-z/MediaObjects/13045_2020_1011_Fig5_HTML.png)
New agents and regimens for diffuse large B cell lymphoma | Journal of Hematology & Oncology | Full Text
![Cancers | Free Full-Text | An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach Cancers | Free Full-Text | An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach](https://www.mdpi.com/cancers/cancers-13-02893/article_deploy/html/images/cancers-13-02893-g003.png)
Cancers | Free Full-Text | An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach
![Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab](https://www.mdpi.com/cancers/cancers-14-01917/article_deploy/html/images/cancers-14-01917-g001.png)
Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
![R-EPOCH May Extend Survival in Patients with Rare Forms of Diffuse Large B-Cell Lymphoma – Consult QD R-EPOCH May Extend Survival in Patients with Rare Forms of Diffuse Large B-Cell Lymphoma – Consult QD](https://consultqd.clevelandclinic.org/wp-content/uploads/sites/2/2019/03/18-CNR-6413_650x450.jpg)